trending Market Intelligence /marketintelligence/en/news-insights/trending/hlaMqj0rBHgYV7q7tBSnnA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Takeda-backed Phathom prices $181.7M IPO at midpoint of given range

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Takeda-backed Phathom prices $181.7M IPO at midpoint of given range

Phathom Pharmaceuticals Inc. priced its IPO of 9,563,157 common shares at $19 each — the midpoint of a previously announced range.

The Buffalo Grove, Ill.-based company previously said it expects to price the IPO at between $18 and $20 per share. The company was launched by Takeda Pharmaceutical Co. Ltd., which owns a 9.1% stake, and private equity firm Frazier Healthcare Partners, which has a 41.1% stake.

Phathom also granted underwriters a 30-day option to buy up to an additional 1,434,473 common shares at the same price.

Gross proceeds are expected to be about $181.7 million. The company previously said it plans to use net proceeds to fund the clinical development of vonoprazan — which was developed by the Japanese drugmaker Takeda and is approved in nine countries in Asia and Latin America.

The medicine is used as a single therapy for gastroesophageal reflux disease and a combination treatment with antibiotics for infection caused by H. pylori bacteria.

Proceeds will also be used for working capital and general corporate purposes.

Phathom's common shares are expected to begin trading on the Nasdaq Global Select Market on Oct. 25 under the PHAT symbol. The IPO is expected to close Oct. 29.

Goldman Sachs & Co. LLC, Jefferies and Evercore ISI are acting as joint book-running managers for the offering, while Needham & Co. is acting as lead manager.

Phathom focuses on therapies for the multibillion-dollar acid-reflux market in the U.S. and Europe.

The company is led by co-founder David Socks, who serves as president, CEO, treasurer, secretary and director. As part of a planned transition, Socks will be succeeded by board member Terrie Curran as CEO.